Logo Logo
Group by: Item Type | Date
Number of items: 3.

Journal article

Dent, S.; Cortes, J.; Im, Y.-H.; Dieras, V.; Harbeck, N.; Krop, I. E.; Wilson, T. R.; Cui, N.; Schimmoller, F.; Hsu, J. Y.; He, J.; De Laurentiis, M.; Sousa, S.; Drullinsky, P. and Jacot, W. (2021): Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. In: Annals of Oncology, Vol. 32, No. 2: pp. 197-207

Baselga, J.; Cortés, J.; De Laurentiis, M.; Diéras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y.-H.; Jacot, W.; Krop, I. E. and Verma, S. (2016): SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors. In: Cancer Research, Vol. 76

Baselga, J.; Cortes Castan, J.; De Laurentiis, M.; Dieras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y.-H.; Jacot, W.; Krop, I. E. and Verma, S. (2016): SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours. In: Annals of Oncology, Vol. 27

This list was generated on Sun Apr 14 06:00:05 2024 CEST.